The US Supreme Court has rejected a challenge from the pharmaceutical industry to a Biden-era policy aimed at curbing Medicare drug prices. The challenge was brought by several drug manufacturers, but the court's decision suggests that the policy, which involves Medicare price negotiations, will stand. The outcome appears to be a significant development for the pharmaceutical industry and Medicare drug pricing.